Health on MSN11mon
What Is Beta Thalassemia?
There are three main types of beta thalassemia: minor, intermedia, and major. Mutations (variants) in the HBB gene (the gene ...
Nature1y
Genetic Mutation
How do mutations happen, and how do they influence ... often resulting in a frameshift One form of beta-thalassemia Deletion One or more nucleotides is "skipped" during replication or otherwise ...
pharmaphorum2y
Commercialization of novel gene-editing technology in beta-thalassemia
Beta-thalassemia is a rare blood disorder caused by a genetic defect in hemoglobin. Several manufacturers are developing novel treatments for the disease, including Vertex, which has partnered ...
BioWorld9d
Yoltech advances gene editing therapy into clinic for β-thalassemia
Yoltech Therapeutics Co. Ltd. has advanced YOLT-204 into the clinic for the treatment of transfusion-dependent β-thalassemia (TDT). If successful, YOLT-204 may provide an off-the-shelf curative ...
EurekAlert!7d
Webinar highlight: High-throughput sequencing accelerates global thalassemia prevention
On January 21st, the Thalassemia International Federation (TIF) and BGI Genomics jointly hosted an educational webinar focused on thalassemia prevention in high-prevalence regions. Experts emphasized ...
Taiwan News9d
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204, an investigational therapy for the ...
Mena FN5d
Alpha Thalassemia Market Anticipated To Witness Robust Growth By 2034, Reports Delveinsight
thalassemia refers specifically to the abnormal or absent manufacturing of alpha-globin chains. These are associated with more than 15 different genetic mutations. The severity of the clinical ...
Medindia9d
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for ß-Thalassemia
YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial for YOLT-204 , an investigational ...